For the Inventor, By the Inventor

Enter assignee name

Scinopharm Taiwan, Ltd.

USPTO Granted Patents = 76

CIPO Patents = 9

EPO Patents = 35

Trademarks = 5

Forward Citations = 87

Loading Chart...

Loading Chart...

111 inventors (with patents filed for the assignee):

Julian Paul Henschke (19 out of 23 patents)

Tsung-Yu Hsiao (12 out of 14 patents)

Tsung-Cheng Hu (10 out of 10 patents)

4. Yung-Fa Chen (10 out of 14 patents)

5. Xiaoheng Zhang (7 out of 9 patents)

6. Yuan-Xiu Liao (5 out of 7 patents)

7. Wen-Wei Lin (5 out of 5 patents)

8. YuanChang Huang (5 out of 5 patents)

9. Shu-Ping Chen (5 out of 8 patents)

10. George Schloemer (5 out of 10 patents)

11. Hardy W Chan (4 out of 5 patents)

12. Ming-Chih Wu (4 out of 4 patents)

13. Wei-Shuo Lo (4 out of 4 patents)

14. Ping-Yu Wu (4 out of 4 patents)

15. Jyh-Hsiung Liao (4 out of 5 patents)

Core Competencies:

Mesoporous Silica Nanoparticles

Semaglutide Purification

Osimertinib Preparation

Crystalline Forms of Ivacaftor

Irinotecan Polymorphism

Olaparib Manufacturing

SGLT2 Inhibitors

Prostaglandin Analogues

Chiral Catalysts

Peptide Chromatographic Purification

High-Throughput Screening

Decitabine Synthesis

76 patents: Sort by Forward Citations

1. 12274688 - Drug-loaded mesoporous silica nanoparticle for prevention and treatment of brain cancers or brain metastases (2025-04-14),

2. 12269844 - Process for purifying semaglutide and liraglutide (2025-04-08),

3. 11780824 - Process for preparing osimertinib or a salt thereof (2023-10-10),

4. 11459354 - Process for purifying liraglutide (2022-10-04),

5. 11384054 - Crystalline form of ivacaftor and a process for preparing the same (2022-07-12),

6. 11339131 - Process for preparing elagolix sodium and intermediates thereof (2022-05-24),

7. 10919905 - Polymorphism for irinotecan free base (2021-02-16),

8. 10703728 - Crystalline form of olaparib and a process for preparing the same (2020-07-07),

9. 10435395 - Crystal forms of lifitegrast (2019-10-08),

10. 10428052 - Process for preparing lifitegrast and intermediates thereof (2019-10-01),

11. 10385142 - Method for preparing sugammadex sodium (2019-08-20),

12. 10138215 - Process for preparing ataluren and its intermediates (2018-11-27),

13. 10138211 - Crystalline forms of olaparib and manufacturing processes therefor (2018-11-27),

14. 10118937 - Process for preparing ixazomib citrate and intermediates therefor (2018-11-06),

15. 10100017 - Processes for preparing olaparib (2018-10-16),

ScinoPharm Taiwan, Ltd. is a leading pharmaceutical company in Taiwan. With over 30 years of experience, ScinoPharm specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) for the global market. They provide high-quality, cost-effective APIs through a reliable supply chain, state-of-the-art facilities, and regulatory compliance. ScinoPharm is committed to delivering innovative solutions to support the success of their partners and contribute to patients' well-being.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

76 Patents

#12 in Tainan

#287 in Taiwan

#9,624 in the World

Scinopharm Taiwan, Ltd.

Forward Citations = 87

111 inventors:

Julian Paul Henschke (19 out of 23 patents)

Tsung-Yu Hsiao (12 out of 14 patents)

Tsung-Cheng Hu (10 out of 10 patents)

4. Yung-Fa Chen (10 out of 14 patents)

5. Xiaoheng Zhang (7 out of 9 patents)

Please report any incorrect information to support@idiyas.com

Loading…